NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: Medical University of Lodz
Conditions: Asthma; Eosinophilic
Interventions: Mepolizumab given SC 100mg every 4 weeks between Dec 2017 and Dec 2019
Countries: Poland
This study is aimed at evaluation of the efficacy of mepolizumab 100 mg subcutaneously (SC) every 4 weeks in patients with severe eosinophilic asthma who have been treated for at least 12 months in several Polish allergy/asthma centres under the same protocol. Target population to be recruited has been set at 130 subjects from at least 6 asthma centers throughout the country. Data on demographics and asthma status will be collected using questionnaires at 3 time-points: pre-mepolizumab (pre-MEPO), after 24 weeks of mepolizumab (MEPO) and after 1 year of MEPO administration (some of the outcomes will be observed every 4 weeks). Primary endpoints will include: * Asthma exacerbations measured at qualification for the treatment (in the period of previous 52 weeks) and at the 24th and 52nd week of the treatment. * Oral Corticosteroids use dose (documented at qualification for the treatment and at the 24th and 52nd week of the treatment).
Sex: ALL
Age: 18 Years to —
Healthy volunteers: No
Study type: OBSERVATIONAL
Inclusion Criteria: \* The availability of the complete data * Duration of treatment with mepolizumab: ≥ 52 weeks * Satisfying the Polish drug programme inclusion criteria: * Age \>18 * Before treatment with mepolizumab (BSAT inclusion criteria): * High doses of inhaled corticosteroids (ICS) + one other controlling medication (i.e. LABA) * ≥2 exacerbations in the previous year * ≥350 eosinophil cells/microliter (µl) in the peripheral blood at the time of qualification or in the previous year * Pre-bronchodilator FEV1 \< 80% Exclusion Criteria: \* Duration of treatment with mepolizumab \< 52 weeks • Lack of complete data
- Lodz, Poland